OCT 19, 2021 8:00 AM PDT

Mild COVID Produces Better Than Expected Antibody Responses

WRITTEN BY: Tara Fernandez

Over millions of years, the immune system has evolved to shield us against disease-causing pathogens that we encounter early in life. When it comes to the coronavirus, immunologists previously believed that only those who recovered from severe infections developed immune protection. 

However, a growing body of research contradicts these earlier sentiments—even those who experienced mild bouts of COVID-19 produced sustained levels of antibodies against the virus.

University of Michigan researcher Charles Schuler led a team that tracked immune responses in recovering COVID patients. Of the 130 study participants, three were hospitalized with severe symptoms, while the rest experienced much milder infection symptoms such as headaches and a loss of smell.

The researchers measured the levels of antibodies against the virus’ spike protein and nucleocapsid at the three- and six-month mark after infection. In results reported in Microbiology Spectrum, 90 percent of the participants had strong antibody levels, suggesting natural immunity shielded against virus reinfection for at least six months.

Throughout the study, none of the participants with circulating neutralizing antibodies got reinfected, while 15 antibody-negative patients did. Interestingly, contrary to earlier hypotheses that the strength of COVID neutralizing antibodies wane over time, Schuler and team found that the patients’ antibodies remained as potent between the three- and six-month marks.

This study represents one of the first to provide evidence for longer-term immunity in those who experience mild COVID infections.

Schuler cautions that while these findings are encouraging for those who have fully recovered from COVID, this is not a reason to skip vaccinations in favor of acquiring natural immunity.

“Vaccination decreases infectiousness, the risk of hospitalization and deaths from COVID-19, without having the actual infection,” commented Schuler. “Achieving natural immunity by deferring vaccination in favor of infection is not worth going through the discomfort, risk to yourself and risk to others.”

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
AUG 25, 2021
Cell & Molecular Biology
Sino Biological's Listing on the Shenzhen Stock Exchange
AUG 25, 2021
Sino Biological's Listing on the Shenzhen Stock Exchange
China, August 16, 2021 - Sino Biological, Inc. (“Sino Biological” or the “Company”), a biot ...
AUG 30, 2021
Cancer
A Hot Approach to CAR T Cells
AUG 30, 2021
A Hot Approach to CAR T Cells
Immunotherapy, a type of treatment that targets a patient’s immune system to enhance the natural ability to attack ...
SEP 16, 2021
Cancer
Inspiring Hope during Childhood Cancer Awareness Month
SEP 16, 2021
Inspiring Hope during Childhood Cancer Awareness Month
Childhood cancers, also known as pediatric cancers, are diagnosed in patients up to 14 years old.  Estimates for 20 ...
OCT 14, 2021
Immunology
'Bio-Betters' Form the Next Wave of Cancer Therapies
OCT 14, 2021
'Bio-Betters' Form the Next Wave of Cancer Therapies
  Antibodies are blood proteins with highly specialized functions: to recognize and eliminate bacteria, viruses, an ...
OCT 12, 2021
Health & Medicine
Atopic Dermatitis: A Harbinger of Autoimmune Diseases?
OCT 12, 2021
Atopic Dermatitis: A Harbinger of Autoimmune Diseases?
New research published in Allergy, Asthma & Clinical Immunology found an increased risk of autoimmune disease develo ...
NOV 16, 2021
Immunology
How a BBQ Lighter Inspired a New Vaccine Technology
NOV 16, 2021
How a BBQ Lighter Inspired a New Vaccine Technology
It’s the size of a pen, weighs as much as two AA batteries, and works without a power source. A new microneedle de ...
Loading Comments...